Octagon Capital Advisors’s Kymera Therapeutics KYMR Stock Holding History

Octagon Capital Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.4M	Sell	425,000 -110,000	-21%	-$8.71M	3.92%	8
2025 Q4	$41.6M	Buy	535,000 +175,000	+49%	+$11.8M	5.05%	6
2025 Q3	$20.4M	Buy	360,000 +94,000	+35%	+$4.24M	3.09%	12
2025 Q2	$11.6M	Buy	+266,000	New	+$9.16M	2.55%	19
2021 Q3	–	Sell	-100,000	Closed	-$4.85M	–	32
2021 Q2	$4.85M	Buy	+100,000	New	+$4.34M	1%	26

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Octagon Capital Advisors's KYMR Position: Q1 2026 in Review

Octagon Capital Advisors reduced its Kymera Therapeutics (KYMR) stake by 21% in Q1 2026, selling an estimated $8.71M and leaving 425,000 shares worth $35.4M. The position accounts for 3.92% of the portfolio, ranked #8.

Octagon Capital Advisors first reported a position in KYMR in Q2 2021 and has held it in 5 quarters since. The position peaked at $41.6M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Octagon Capital Advisors held 425,000 shares of Kymera Therapeutics worth $35.4M as of Q1 2026.
Octagon Capital Advisors sold 110,000 Kymera Therapeutics shares in Q1 2026, an estimated $8.71M.
Kymera Therapeutics made up 3.92% of Octagon Capital Advisors's portfolio in Q1 2026, its #8 holding.
Octagon Capital Advisors first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 5 quarters since.
Octagon Capital Advisors's Kymera Therapeutics position peaked at $41.6M in Q4 2025.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.